Cara Therapeutics, Inc.
NASDAQ: CARA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher A. Posner
- Employees
- 10
- Headquarters
- Stamford, United States
- IPO year
- 2014
- Market cap
- $8.1M
- Website
- https://www.caratherapeutics.com
Loading CARA…
Loading profile data…Frequently asked questions about CARA
What does Cara Therapeutics, Inc. (CARA) do?
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline i...
Where does CARA trade?
Cara Therapeutics, Inc. (CARA) trades on the NASDAQ Global Market.
What sector is CARA in?
Cara Therapeutics, Inc. (CARA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cara Therapeutics, Inc.?
Christopher A. Posner is the chief executive officer of Cara Therapeutics, Inc. (CARA).
Where is Cara Therapeutics, Inc. headquartered?
Cara Therapeutics, Inc. is headquartered in United States.
Does CARA pay a dividend?
Cara Therapeutics, Inc. (CARA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CARA go public?
Cara Therapeutics, Inc. (CARA) completed its initial public offering in 2014.